journal article·2021-06-23

A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise

Meng Tian, Rui Xing, Juan Guan, Bingxue Yang, Xin Zhao, Juanjuan Yang, Changyou Zhan, Shiyi Zhang

Nano Letters· Volume 21· Issue 12
Publisher page

Abstract

Cancer patients suffer from the toxicity of chemotherapy. Antidote, given as a remedy limiting poison, is an effective way to counteract toxicity. However, few antidotes abrogate chemotoxicity without compromising the therapeutic efficacy. Herein, a rationally designed nanoantidote can neutralize chemo-agents in normal cells but not enter tumors and thus would not interfere with the efficacy of tumor treatment. The nanoantidote, consisting of a dendrimer core wrapped by reductive cysteine, captures Temozolomide (TMZ, the glioblastoma standard chemotherapy). Meanwhile, thanks to the blood-brain barrier (BBB) and the size of the nanoantidote, the nanoantidote cannot enter glioblastoma. In murine models, the nanoantidote distributes in normal tissues without crossing the BBB, so it markedly reduces the chemotoxicity of TMZ and retains the original TMZ therapeutic efficacy. With most nanotechnologies focusing on antitumor treatment, this detoxicating strategy demonstrates a nanoplatform to reduce chemotoxicity using physiology barriers and introduces a new approach to nanomedicine for cancer chemotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dendrimers and Hyperbranched Polymers · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, People’s Republic of China

Department of Pharmacology, School of Basic Medical Sciences and Center of Medical Research and Innovation, Shanghai Pudong Hospital and State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200032, P.R. China

School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, People’s Republic of China

Funding

Shanghai Jiao Tong University · State Key Laboratory of Oncogenes and Related Genes · Youth Thousand-Talents Program of China

References (55)

Show source-provided references
1. 10.1001/jamaoncol.2017.460610.1001/jamaoncol.2017.4606 ↗
2. 10.1056/NEJMoa02234010.1056/NEJMoa022340 ↗
3. 10.1016/S0140-6736(02)08938-910.1016/S0140-6736(02)08938-9 ↗
4. 10.1056/NEJM19871210317240210.1056/NEJM198712103172402 ↗
5. 10.1016/S0140-6736(09)61299-X10.1016/S0140-6736(09)61299-X ↗
6. 10.1056/NEJMsa06018510.1056/NEJMsa060185 ↗
7. 10.1016/S1470-2045(02)00773-810.1016/S1470-2045(02)00773-8 ↗
8. 10.1038/sj.bjc.660349810.1038/sj.bjc.6603498 ↗
9. 10.1016/0002-9343(80)90472-610.1016/0002-9343(80)90472-6 ↗
10. 10.1038/nrclinonc.2010.8210.1038/nrclinonc.2010.82 ↗
11. 10.1056/NEJMra120256110.1056/NEJMra1202561 ↗
12. 10.1001/jama.2014.48110.1001/jama.2014.481 ↗
13. 10.1056/NEJM19920618326250710.1056/NEJM199206183262507 ↗
14. 10.1056/NEJM20010208344060510.1056/NEJM200102083440605 ↗
15. 10.1200/jco.2010.28.15_suppl.908410.1200/jco.2010.28.15_suppl.9084 ↗
16. 10.1126/scitranslmed.300873610.1126/scitranslmed.3008736 ↗
17. 10.1038/nnano.2013.5410.1038/nnano.2013.54 ↗
18. 10.1038/nbt102310.1038/nbt1023 ↗
19. 10.1038/nbt.303710.1038/nbt.3037 ↗
20. 10.1038/s41467-019-10296-910.1038/s41467-019-10296-9 ↗
21. 10.1038/nnano.2007.33910.1038/nnano.2007.339 ↗
22. 10.1001/archneur.63.3.33710.1001/archneur.63.3.337 ↗
23. 10.1016/j.biomaterials.2019.11949110.1016/j.biomaterials.2019.119491 ↗
24. 10.1016/j.drudis.2006.10.01310.1016/j.drudis.2006.10.013 ↗
25. 10.1038/nrc156610.1038/nrc1566 ↗
26. 10.1146/annurev-med-040210-16254410.1146/annurev-med-040210-162544 ↗
27. 10.1038/nmat377610.1038/nmat3776 ↗
28. 10.1016/j.jconrel.2020.02.00810.1016/j.jconrel.2020.02.008 ↗
29. 10.1016/j.apmt.2018.05.00210.1016/j.apmt.2018.05.002 ↗
30. 10.3892/or.2016.534210.3892/or.2016.5342 ↗
31. 10.1016/j.theochem.2006.08.01210.1016/j.theochem.2006.08.012 ↗
32. 10.1021/acs.nanolett.9b0177410.1021/acs.nanolett.9b01774 ↗
33. 10.1021/acsnano.6b0005310.1021/acsnano.6b00053 ↗
34. 10.1021/acs.nanolett.0c0398210.1021/acs.nanolett.0c03982 ↗
35. 10.1038/s41467-019-12470-510.1038/s41467-019-12470-5 ↗
36. 10.1002/ange.20191218210.1002/ange.201912182 ↗
37. 10.1021/acs.nanolett.8b0192410.1021/acs.nanolett.8b01924 ↗
38. 10.1002/adma.20180130410.1002/adma.201801304 ↗
39. 10.1182/blood.V124.21.1602.160210.1182/blood.V124.21.1602.1602 ↗
40. 10.1056/NEJMoa161197710.1056/NEJMoa1611977 ↗
41. 10.1007/s00066-010-2132-310.1007/s00066-010-2132-3 ↗
42. 10.1021/acs.chemrestox.9b0015210.1021/acs.chemrestox.9b00152 ↗
43. 10.2165/00003495-199957030-0000310.2165/00003495-199957030-00003 ↗
44. Kizilarslanoglu M. C. · J. BUON · 2011 · 16 · 547
45. 10.1097/01.mph.0000212996.94929.0b10.1097/01.mph.0000212996.94929.0b ↗
46. 10.1002/ijc.291061052010.1002/ijc.2910610520 ↗
47. 10.1007/s10620-012-2493-910.1007/s10620-012-2493-9 ↗
48. 10.1056/NEJMra181614910.1056/NEJMra1816149 ↗
49. 10.1038/s41573-019-0048-x10.1038/s41573-019-0048-x ↗
50. 10.1038/ajg.2016.51710.1038/ajg.2016.517 ↗
51. 10.1016/j.tips.2020.06.01110.1016/j.tips.2020.06.011 ↗
52. 10.1016/j.heares.2004.02.00710.1016/j.heares.2004.02.007 ↗
53. Neuwelt E. A. · Cancer Res. · 2001 · 61 · 7868
54. 10.1021/jm501535r10.1021/jm501535r ↗
55. 10.1016/j.nantod.2019.10076510.1016/j.nantod.2019.100765 ↗